Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-02-15 / Cytotherapy 2017 04;19(4):500-513Targeting therapy-resistant cancer stem cells by hyperthermia
/in Hyperthermia, International Publications /von 2017-02-02 / Int J Hyperthermia 2017 Jun;33(4):419-427Short-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study
/in Colorectal Cancer, Hyperthermia, International Publications /von 2017-02-02 / Int J Hyperthermia 2017 Feb;:1-9Artikel über Stefaan Van Gool als Kinderneuroonkologe in der Washington Post
/in IOZK In der Presse /von IOZKHistory and current state of immunotherapy in glioma and brain metastasis
/in Glioblastoma, International Publications /von 2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-368A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-76
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution